Pharmaxis Ltd. faces the prospect of having to conduct a new clinical trial of Bronchitol (mannitol inhalation powder) in adult and pediatric cystic fibrosis patients now that FDA has issued a “complete response” letter citing inadequate evidence of efficacy.
On March 19, the Australian specialty pharmaceutical company announced that FDA declined to approve its NDA for dry powder mannitol...